CytomX Therapeutics, Inc. - Current Ratio

The Current Ratio as of June 2026 (TTM) for CytomX Therapeutics, Inc. (CTMX) is 10.38

According to CytomX Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.38. This represents a change of 94.90% compared to the average of 5.32 of the last 4 quarters.

CytomX Therapeutics, Inc. (CTMX) Historical Current Ratio (quarterly & annually)

How has CTMX Current Ratio performed in the past?

The mean historical Current Ratio of CytomX Therapeutics, Inc. over the last ten years is 3.55. The current 10.38 Current Ratio has changed 29.12% with respect to the historical average. Over the past ten years (40 quarters), CTMX's Current Ratio was at its highest in in the March 2026 quarter at 10.38. The Current Ratio was at its lowest in in the June 2024 quarter at 1.00.

CytomX Therapeutics, Inc. (CTMX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of CytomX Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

CytomX Therapeutics, Inc. (CTMX) Average Current Ratio

How has CTMX Current Ratio performed in the past?

The current Current Ratio of CytomX Therapeutics, Inc. (CTMX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

CytomX Therapeutics, Inc. (CTMX) Current Ratio vs. Peers

How is CTMX’s Current Ratio compared to its peers?

CytomX Therapeutics, Inc.’s Current Ratio is greater than Erasca, Inc. (9.52), greater than Iovance Biotherapeutics, Inc. (3.60), less than MBX Biosciences, Inc. Common Stock (30.79), less than ArriVent BioPharma, Inc. Common Stock (13.95), greater than MeiraGTx Holdings plc (0.55), less than Astria Therapeutics, Inc. (10.78), greater than MoonLake Immunotherapeutics (8.60), greater than Replimune Group, Inc. (5.60), greater than Ginkgo Bioworks Holdings, Inc. (5.15), less than Anavex Life Sciences Corp. (20.87),

Build a custom stock screener for CytomX Therapeutics, Inc. (CTMX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CytomX Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CytomX Therapeutics, Inc. (CTMX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CytomX Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.